|
Administration
Should be taken with food.
|
|
Contraindications
Hypersensitivity.
|
|
Special Precautions
Patient with CNS disease (e.g. multiple sclerosis, epilepsy). Patient undergoing haemodialysis. Hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause somnolence, dizziness, or temporary loss of consciousness, if affected, do not drive or operate machinery.
|
|
Adverse Reactions
Blood and lymphatic system disorders: Rarely, leucopenia.
Ear and labyrinth disorders: Very rarely, vertigo.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, epigastric discomfort, dry mouth. Rarely, impaired sense of taste.
General disorders and administration site conditions: Fatigue.
Hepatobiliary disorders: Jaundice.
Investigations: Abnormal LFT.
Metabolism and nutrition disorders: Loss of appetite.
Nervous system disorders: Very rarely, somnolence, headache, dizziness, tremor, rigidity, coordination impairments, seizures, temporary loss of consciousness, sensory or mixed peripheral neuropathy.
Skin and subcutaneous tissue disorders: Rarely, pruritus and skin reactions.
|
|
Drug Interactions
Potentiates the effect of coumarin-type oral anticoagulants. Prolongs the muscle relaxant effect of vecuronium bromide.
|
|
CIMS Class
|
|
ATC Classification
G01AF06 - ornidazole ; Belongs to the class of imidazole derivative antiinfectives. Used in the treatment of gynecological infections.
J01XD03 - ornidazole ; Belongs to the class of imidazole derivative antibacterials. Used in the systemic treatment of infections. P01AB03 - ornidazole ; Belongs to the class of nitroimidazole derivatives antiprotozoals. Used in the treatment amoebiasis and other protozoal diseases. |
Sign Out
